Nuvectis Pharma, Inc. Forecasted to Post FY2028 Earnings of $3.90 Per Share (NASDAQ:NVCT)

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Investment analysts at Roth Capital upped their FY2028 earnings per share estimates for shares of Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 7th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of $3.90 per share for the year, up from their prior forecast of $3.59. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share.

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a research report on Wednesday.

Nuvectis Pharma Stock Performance

Nuvectis Pharma stock opened at $6.38 on Thursday. The company has a 50 day moving average price of $8.10 and a 200 day moving average price of $8.20. The firm has a market capitalization of $117.21 million, a price-to-earnings ratio of -4.46 and a beta of 0.45. Nuvectis Pharma has a 52 week low of $5.92 and a 52 week high of $18.65.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01).

Insider Buying and Selling at Nuvectis Pharma

In other news, CEO Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock in a transaction dated Monday, March 18th. The stock was acquired at an average cost of $10.29 per share, for a total transaction of $51,450.00. Following the acquisition, the chief executive officer now directly owns 3,242,484 shares in the company, valued at $33,365,160.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 38.85% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds have recently bought and sold shares of NVCT. Strs Ohio raised its stake in shares of Nuvectis Pharma by 59.0% in the 4th quarter. Strs Ohio now owns 6,200 shares of the company’s stock valued at $51,000 after acquiring an additional 2,300 shares in the last quarter. Blue Zone Wealth Advisors LLC acquired a new position in Nuvectis Pharma in the 1st quarter valued at $118,000. Edmond DE Rothschild Holding S.A. acquired a new position in Nuvectis Pharma during the 4th quarter worth $160,000. Finally, Baldwin Brothers LLC MA boosted its holdings in Nuvectis Pharma by 22.0% during the fourth quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock valued at $1,185,000 after acquiring an additional 25,660 shares during the period. 96.77% of the stock is owned by institutional investors and hedge funds.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.